Go To Global Site
Welcome to UCB in the United States

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Jan

12

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Nov

30

World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

Nov

17

UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy